| Revision as of 05:28, 1 July 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|err← Previous edit |
Latest revision as of 22:13, 31 March 2024 edit undoAnomieBOT (talk | contribs)Bots6,568,435 editsm Dating maintenance tags: {{Better source needed}} |
| (111 intermediate revisions by 53 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Anti-diabetic drug}} |
|
{{drugbox |
|
|
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
| Watchedfields = changed |
|
|
| verifiedrevid = 454952697 |
|
|
| image = Alogliptin.svg |
|
|
| alt = |
|
|
|
|
|
<!--Clinical data--> |
|
|
| pronounce = |
|
|
| tradename = Nesina, Vipidia<br />Kazano, Vipidomet (with ])<br />Oseni, Incresync (with ]) |
|
|
| Drugs.com = {{drugs.com|monograph|alogliptin}} |
|
|
| MedlinePlus = a613026 |
|
|
| licence_EU = yes |
|
|
| DailyMedID = Alogliptin |
|
|
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) --> |
|
|
| pregnancy_AU = B3 |
|
|
| pregnancy_AU_comment = |
|
|
| pregnancy_US = B |
|
|
| pregnancy_US_comment = |
|
|
| pregnancy_category = |
|
|
| routes_of_administration = ] |
|
|
| ATC_prefix = A10 |
|
|
| ATC_suffix = BH04 |
|
|
|
|
|
| legal_AU = S4 |
|
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
|
| legal_US = Rx-only |
|
|
| legal_EU = Rx-only |
|
|
| legal_status = Rx-only |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
|
| bioavailability = 100% |
|
|
| protein_bound = 20% |
|
|
| metabolism = Limited, ] (]- and ]-mediated) |
|
|
| elimination_half-life = 12–21 hours |
|
|
| excretion = ] (major)<ref name=AACE/> and fecal (minor) |
|
|
|
|
|
<!--Identifiers--> |
|
|
| IUPHAR_ligand = 6319 |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
|
| CAS_number = 850649-61-5 |
|
|
| PubChem = 11450633 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
|
| DrugBank = |
|
|
| ChEBI_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEBI = 72323 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII = JHC049LO86 |
|
| UNII = JHC049LO86 |
|
| verifiedrevid = 403344282 |
|
|
| IUPAC_name = 2-({6--3-methyl-2,4-dioxo-<br>3,4-dihydropyrimidin-1(2''H'')-yl}methyl)benzonitrile |
|
|
| image = Alogliptin.svg |
|
|
| CAS_number = 850649-62-6 |
|
|
| ATC_prefix = A10 |
|
|
| ATC_suffix = BH04 |
|
|
| PubChem = 11450633 |
|
|
| DrugBank = |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D06553 |
|
| KEGG = D06553 |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL = 376359 |
|
| ChEMBL = 376359 |
|
|
| synonyms = SYR-322 |
|
| C=18|H=21|N=5|O=2 |
|
|
|
|
|
| molecular_weight = 339.39 g/mol |
|
|
|
| index2_label = benzoate |
|
| smiles = N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2 |
|
|
|
| CAS_number2_Ref = {{cascite|correct|CAS}} |
|
| bioavailability = |
|
|
|
| CAS_number2 = 850649-62-6 |
|
| protein_bound = |
|
|
|
| UNII2_Ref = {{fdacite|correct|FDA}} |
|
| metabolism = |
|
|
|
| UNII2 = EEN99869SC |
|
| elimination_half-life = |
|
|
|
|
|
| excretion = |
|
|
|
<!--Chemical data--> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
|
| IUPAC_name = 2-({6--3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2''H'')-yl}methyl)benzonitrile |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
|
|
| C=18 | H=21 | N=5 | O=2 |
|
| pregnancy_category= |
|
|
|
| smiles = N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2 |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
|
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
| ChemSpiderID = 9625485 |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
|
| StdInChI = 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 |
|
| legal_status = |
|
|
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| routes_of_administration = Oral |
|
|
|
| StdInChIKey = ZSBOMTDTBDDKMP-OAHLLOKOSA-N |
|
}} |
|
}} |
|
'''Alogliptin''' (codenamed '''SYR-322''') is an investigational ] in the ] class,<ref name="pmid17441705">{{cite journal |author=Feng J, Zhang Z, Wallace MB, ''et al.'' |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV |journal=] |volume=50 |issue=10 |pages=2297–300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l}}</ref> being developed by ]. In January 2008, Takeda submitted a ] for alogliptin to the U.S. ], after positive results from ] ]s.<ref>{{cite press release | url = http://www.takeda.com/press/article_28864.html | title = Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | date = January 4, 2008 | accessdate = 2008-01-09 | publisher = ]}}</ref> However, the FDA submission was suspended or withdrawn in June 2009 needing more data.<ref>{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=55661199&source=genwire|title=GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy|date=4 June 2009|publisher=Genetic Engineering and Biotechnology News}}</ref> |
|
|
|
|
|
|
|
'''Alogliptin''', sold under the brand names '''Nesina''' and '''Vipidia''',<ref name=takedapr28864/><ref name=EMA2018>{{cite web |title=Vipidia |url=https://www.ema.europa.eu/documents/overview/vipidia-epar-summary-public_en.pdf |publisher=European Medicines Agency |access-date=31 March 2024 |archive-url=https://web.archive.org/web/20181101160452/https://www.ema.europa.eu/documents/overview/vipidia-epar-summary-public_en.pdf |archive-date=1 November 2018 |url-status=dead }}</ref> is an oral ] in the ] (gliptin) class.<ref name=pmid17441705/> Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity.<ref name=AACE/> Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.<ref name=AACE>{{cite web |url=https://www.aace.com/files/algorithm-07-11-2013.pdf |title=www.aace.com |archive-url=https://web.archive.org/web/20181101160532/https://www.aace.com/files/algorithm-07-11-2013.pdf |archive-date=2018-11-01 |url-status=dead }}</ref> |
|
==References== |
|
|
|
|
|
{{reflist}} |
|
|
|
In April 2016, the U.S. ] (FDA) added a warning about increased risk of ].<ref name=FDA2016>{{cite web|title= FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes |website=U.S. Food and Drug Administration (FDA) |access-date=16 March 2018 }}</ref> It was developed by Syrrx, a company which was acquired by ] in 2005.<ref>{{Cite web|url=http://www.utsandiego.com/uniontrib/20050208/news_1b8syrrx.html|title = The San Diego Union-Tribune - San Diego, California & National News}}</ref> In 2020, it was the 295th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.<ref>{{cite web | title = The Top 300 of 2020 | url = https://clincalc.com/DrugStats/Top300Drugs.aspx | website = ClinCalc | access-date = 7 October 2022}}</ref><ref>{{cite web | title = Alogliptin - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Alogliptin | access-date = 7 October 2022}}</ref> |
|
|
|
|
|
==Medical uses== |
|
|
Alogliptin is a ] (DDP-4) that decreases blood sugar levels similar to other DPP-4 inhibitors.<ref>{{cite journal | vauthors = Saisho Y | title = Alogliptin benzoate for management of type 2 diabetes | journal = Vascular Health and Risk Management | volume = 11 | pages = 229–243 | date = 2015 | pmid = 25914541 | pmc = 4401208 | doi = 10.2147/VHRM.S68564 | doi-access = free }}</ref> |
|
|
|
|
|
==Side effects== |
|
|
Adverse events include ],<ref name=seino2011/><ref name=kutoh2012/><ref name=bosi2011/> ] (itching),<ref name=EMA2018/> ], headache, and ].<ref name=FDA_Nesina/> It may also cause joint pain that can be severe and disabling.<ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|website=U.S. Food and Drug Administration (FDA)|access-date=1 September 2015|date=2015-08-28}}</ref> Like other DDP-4 inhibitors, alogliptin is weight-neutral.<ref name=AACE/> |
|
|
|
|
|
A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events.<ref>{{cite journal | vauthors = White WB, Zannad F | title = Saxagliptin, alogliptin, and cardiovascular outcomes | journal = The New England Journal of Medicine | volume = 370 | issue = 5 | pages = 484 | date = January 2014 | pmid = 24482824 | doi = 10.1056/NEJMc1313880 }}</ref>{{better source needed|reason=This is a letter to the editor.|date=March 2024}} In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of ].<ref name=FDA2016/> |
|
|
|
|
|
==Market access== |
|
|
] |
|
|
In December 2007, Takeda submitted a ] (NDA) for alogliptin to the ] (FDA),<ref name=grogan2012/> after positive results from ].<ref name=takedapr28864/> In September 2008, the company also filed for approval in Japan,<ref name=geneng2009/> winning approval in April 2010.<ref name=grogan2012/> The company also filed a ] elsewhere outside the United States, which was withdrawn in June 2009 needing more data.<ref name=geneng2009/> The first NDA failed to gain approval and was followed by a pair of NDAs (one for alogliptin and a second for a combination of alogliptin and ]) in July 2011.<ref name=grogan2012/> In 2012, Takeda received a negative response from the FDA on both of these NDAs, citing a need for additional data.<ref name=grogan2012/> |
|
|
|
|
|
In 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina,<ref name="FDA_Nesina">{{cite web |title=Highlights of Prescribing Information: Nesina |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref> combined with ] using the name Kazano,<ref name="FDA_Kazano">{{cite web |title=Highlights of Prescribing Information: Kazano |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203414s000lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref> and when combined with ] as Oseni.<ref name="FDA_Oseni">{{cite web |title=Highlights of Prescribing Information: Oseni |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022426s005lbl.pdf |publisher=US Food and Drug Administration |access-date=31 March 2024}}</ref>{{clear}} |
|
|
|
|
|
== References == |
|
|
{{reflist|refs= |
|
|
|
|
|
<ref name=geneng2009>{{cite news |url=http://www.genengnews.com/news/bnitem.aspx?name=55661199 |title=GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy |date=June 4, 2009 |publisher=]}}</ref> |
|
|
|
|
|
<ref name=grogan2012>{{Citation | vauthors = Grogan K |date=April 26, 2012 |title=FDA wants yet more data on Takeda diabetes drug alogliptin |periodical=] |at=PharmaTimes online | publisher=PharmaTimes |access-date=April 26, 2012 |url=http://www.pharmatimes.com/Article/12-04-26/FDA_wants_yet_more_data_on_Takeda_diabetes_drug_alogliptin.aspx }}</ref> |
|
|
|
|
|
<ref name=pmid17441705>{{cite journal | vauthors = Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL | display-authors = 6 | title = Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 10 | pages = 2297–2300 | date = May 2007 | pmid = 17441705 | doi = 10.1021/jm070104l }}</ref> |
|
|
|
|
|
<ref name=seino2011>{{cite journal | vauthors = Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K | title = Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study | journal = Current Medical Research and Opinion | volume = 27 | issue = 9 | pages = 1781–1792 | date = September 2011 | pmid = 21806314 | doi = 10.1185/03007995.2011.599371 | s2cid = 24082863 }}</ref> |
|
|
|
|
|
<ref name=kutoh2012>{{cite journal | vauthors = Kutoh E, Ukai Y | title = Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial | journal = Endocrine | volume = 41 | issue = 3 | pages = 435–441 | date = June 2012 | pmid = 22249941 | doi = 10.1007/s12020-012-9596-0 | s2cid = 45948727 | publication-date = January 17, 2012 }}</ref> |
|
|
|
|
|
<ref name=bosi2011>{{cite journal | vauthors = Bosi E, Ellis GC, Wilson CA, Fleck PR | title = Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study | journal = Diabetes, Obesity & Metabolism | volume = 13 | issue = 12 | pages = 1088–1096 | date = December 2011 | pmid = 21733058 | doi = 10.1111/j.1463-1326.2011.01463.x | s2cid = 1092260 | publication-date = October 27, 2011 }}</ref> |
|
|
|
|
|
<ref name=takedapr28864>{{cite press release |url=https://www.takeda.com/en-us/newsroom/news-releases/2008/takeda-submits-new-drug-application-for-alogliptin-syr-322-in-the-u.s/ |title=Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. |date=January 3, 2008 |access-date=March 11, 2021 |publisher=] }}</ref> |
|
|
}} |
|
|
|
|
|
== External links == |
|
|
* {{Commons category-inline}} |
|
|
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/850649-61-5 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Alogliptin }} |
|
|
|
|
|
{{Oral hypoglycemics}} |
|
{{Oral hypoglycemics}} |
|
|
{{Portal bar | Medicine}} |
|
|
|
|
|
] |
|
] |
| Line 46: |
Line 122: |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
] |
|
|
|
|
|
] |
|
{{gastrointestinal-drug-stub}} |
|